Equities

Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Actions
  • Price (EUR)3.55
  • Today's Change0.182 / 5.40%
  • Shares traded100.00
  • 1 Year change-57.10%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 16:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

  • Revenue in USD (TTM)200.52m
  • Net income in USD-306.74m
  • Incorporated2000
  • Employees796.00
  • Location
    Pacific Biosciences of California Inc1305 O'brien DriveMENLO PARK 94025United StatesUSA
  • Phone+1 (650) 521-8000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.pacb.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PACB:NSQ since
announced
Transaction
value
Apton Biosystems IncAnnounced02 Aug 202302 Aug 2023Announced-71.89%110.00m
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.